ArticleScientific reports2025
Expression of miRNA-338-3p/miRNA-1250-5p/miRNA-3065-5p clusters in peripheral blood mononuclear cells of ischemic stroke.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic review and meta-analysis of stroke blood biomarker data highlights need for more translational research methods.Nature communications · 2026Pooled it
- A systematic review of MicroRNA (miRNA) biomarkers in the diagnosis and prognosis of hepatocellular carcinoma.Irish journal of medical science · 2026Pooled it
- The Role and Diagnostic Efficacy of the METTL14/GADD45B mCellular and molecular neurobiology · 2026Article
- Targeting Epigenetics in Ischemic Stroke: From Mechanisms to Therapeutics.Current neuropharmacology · 2026Review
- MiR338-3p expression in extracellular vesicles after severe trauma with or without traumatic brain injury.Brain communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To estimate the correlation between miRNA-338-3p/miRNA-1250-5p/miRNA-3065-5p clusters and ischemic stroke (IS). 83 hospitalized patients diagnosed with IS (experimental group) and 50 healthy subjects (control group) were enrolled in the Affiliated Hospital of North Sichuan Medical College from July 2020 to December 2020. The levels of miRNA-338-3p, miRNA-1250-5p, and miRNA-3065-5p in peripheral blood mononuclear cells (PBMCs) were measured by real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR). The expressions of miRNA-1250-5p and miRNA-3065-5p were significantly higher in the experimental group compared to the control group (2.04 ± 0.22 vs. 1.54 ± 0.33, P = 0.002, 6.41 ± 2.17 vs. 1.42 ± 0.24, P < 0.001, respectively) No significant difference in miRNA-338-3p expression was observed between the experimental and control groups (1.87 ± 0.22 vs. 1.25 ± 0.11, P = 0.309). The expression levels of miRNA-1250-5p increased after 24 h and no more than 7 days of disease progression but decreased after 7 days compared to baseline (P < 0.05). The expression levels of miRNA-3065-5p and miRNA-338-3p in patients with a discharge National Institutes of Health Stroke Scale (NIHSS) score greater than 33 were higher than those in the group with a score of 3 or less (P < 0.05). Additionally, the expression level of miRNA-3065-5p in patients with discharged mRS scores of 3 or higher was greater than in patients with discharged mRS scores of 2 or lower (P < 0.05). The miRNA-338-3p/miRNA-1250-5p/miRNA-3065-5p clusters showed a positive correlation with neutrophil percentage and a negative correlation with lymphocyte percentage (P < 0.05). Furthermore, miRNA-338-3p, miRNA-1250-5p, and miRNA-3065-5p significantly correlated in IS (P < 0.001). miRNA-1250-5p and miRNA-3065-5p may be associated with IS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.